Top
Summary
All studies
Mortality
ICU
Hospitalization
RCTs
RCT mortality
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All pegipanermin studies
..
Feedback
Home
c19early.org COVID-19 treatment researchPegipanerminPegipanermin (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 pegipanermin studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Mortality   ICU   Hospitalization   RCTs   RCT mortality   All outcomes  
0 0.5 1 1.5+ All studies -290% 1 77 Improvement, Studies, Patients Relative Risk Mortality -290% 1 77 ICU admission -241% 1 77 Hospitalization -38% 1 77 RCTs -290% 1 77 Late -290% 1 77 Pegipanermin for COVID-19 c19early.org November 2025 Favorspegipanermin Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -290% 3.90 [0.46-33.3] death 4/39 1/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk All studies -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk 1 pegipanermin COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -290% 3.90 [0.46-33.3] 4/39 1/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk All studies -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk 1 pegipanermin COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -241% 3.41 [0.76-15.4] 7/39 2/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.11 Late treatment -241% 3.41 [0.76-15.4] 7/39 2/38 241% higher risk All studies -241% 3.41 [0.76-15.4] 7/39 2/38 241% higher risk 1 pegipanermin COVID-19 ICU result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.11 Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -38% 1.38 [0.88-2.16] hosp. time 39 (n) 38 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.16 Late treatment -38% 1.38 [0.88-2.16] 39 (n) 38 (n) 38% higher risk All studies -38% 1.38 [0.88-2.16] 39 (n) 38 (n) 38% higher risk 1 pegipanermin COVID-19 hospitalization result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.16 Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -290% 3.90 [0.46-33.3] death 4/39 1/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk All studies -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk 1 pegipanermin COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Effect extraction pre-specified(most serious outcome) Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -290% 3.90 [0.46-33.3] 4/39 1/38 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Late treatment -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk All studies -290% 3.90 [0.46-33.3] 4/39 1/38 290% higher risk 1 pegipanermin COVID-19 RCT mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Favors pegipanermin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tesi (DB RCT) -290% 3.90 [0.46-33.3] death 4/39 1/38 Improvement, RR [CI] Treatment Control Tesi (DB RCT) -241% 3.41 [0.76-15.4] ICU 7/39 2/38 Tesi (DB RCT) -62% 1.62 [0.65-4.03] progression 10/39 6/38 Tesi (DB RCT) -38% 1.38 [0.88-2.16] hosp. time 39 (n) 38 (n) Pegipanermin COVID-19 outcomes c19early.org November 2025 Favors pegipanermin Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0